skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

1181 Total results for product and free and sample content found

Scrip, Pink Sheet

Webinar: What’s the Reality of Real World Evidence?

By Mary Jo Laffler 19 Feb 2019

The data and analysis for this webinar were drawn from Pink Sheet and Scrip, both part of the Informa Pharma Intelligence suite of intelligence solutions.

Citeline

New Clinerion And Citeline Partnership Simplifies and Strengthens Matchmaking Between Clinical Researchers and Qualified Patients

19 Feb 2019

Collaboration between two companies leads to more informed decisions for clinical researchers, grounded in real-world evidence

Topic Clinical trials

HBW Insight

France's OTC Market in 2018: Self-Medication Sales Slump, Sanofi Claims Number-One Spot

14 Feb 2019

France's self-medication market had a difficult 2018, due to a weak flu season and changing dynamics in the sector, according to industry association Afipa. Despite this it was a good year for Sanofi, which overtook Boiron as the number-one OTC firm in the market, while its Doliprane analgesic became France's best-selling brand.

Topic Drug review

Generics Bulletin

Alvogen Claims Lead On Lenalidomide In Europe

14 Feb 2019

Alvogen is claiming the first European launch of a generic rival to Revlimid, rolling out the oncology drug in several central and eastern European markets. Meanwhile, IPR challenges to three Revlimid patents in the US have been denied.

Topic Drug review

Pink Sheet

Big Pharma CEOs Get Ready To Testify Preparing For A No Win Situation

By Michael McCaughan 14 Feb 2019

Here is what to expect from – and some free advice for – seven industry executives as they prepare for a hearing on drug pricing in the Senate Finance Committee.

Topic Drug approval

Medtech Insight

New Device Tax Repeal Bills Are Coming, With Candidate Klobuchar's Help

By Ferdous Al-Faruque 14 Feb 2019

Despite a recent report that Sen. Amy Klobuchar, D-Minn., is backing away from leading efforts to repeal the medical device tax due to her presidential ambitions, sources say she is working with Sen. Pat Toomey, R-Pa., to cosponsor a repeal bill this year. Similarly, on the US House-side, Rep. Ron Kind, D-Wisc., is calling on his colleagues to support a full repeal bill as well.

Topic Medtech

Medtech Insight

One In Three Medtech Innovators Will Be 'Driven Out Of Business' By EU MDR, German Business Survey Finds

By Ashley Yeo 14 Feb 2019

The EU Medical Device Regulation is 15 months away from being implemented in full, and a new German survey about its potential impact on the medtech innovation and patient-care landscape makes for sobering reading.

Topic Medtech

Scrip

In NASH, Gilead Swung For The Fences And Struck Out Again

By Joseph Haas 14 Feb 2019

Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.

Topic Drug review Drug approval Drug development landscape Clinical trials

Scrip

Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

By John Davis 14 Feb 2019

Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.

Topic Cancer

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: